HUTCHMED (China) Ltd has a consensus price target of $35.27, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Deutsche Bank, Goldman Sachs, and Cantor Fitzgerald on November 24, 2023, November 10, 2023, and September 5, 2023. With an average price target of $29.7 between Deutsche Bank, Goldman Sachs, and Cantor Fitzgerald, there's an implied 61.33% upside for HUTCHMED (China) Ltd from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
11/24/2023 | HCM | Buy Now | HUTCHMED (China) | $18.41 | 20.04% | Deutsche Bank | Cyrus Ng | $20 → $22.1 | Upgrade | Hold → Buy | Get Alert |
11/10/2023 | HCM | Buy Now | HUTCHMED (China) | $18.41 | -7.66% | Goldman Sachs | Paul Choi | $15 → $17 | Maintains | Neutral | Get Alert |
09/05/2023 | HCM | Buy Now | HUTCHMED (China) | $18.41 | 171.59% | Cantor Fitzgerald | Louise Chen | → $50 | Reiterates | Overweight → Overweight | Get Alert |
07/24/2023 | HCM | Buy Now | HUTCHMED (China) | $18.41 | 171.59% | Cantor Fitzgerald | Louise Chen | → $50 | Reiterates | Overweight → Overweight | Get Alert |
08/09/2022 | HCM | Buy Now | HUTCHMED (China) | $18.41 | -13.09% | Goldman Sachs | Paul Choi | $14 → $16 | Maintains | Neutral | Get Alert |
08/02/2022 | HCM | Buy Now | HUTCHMED (China) | $18.41 | -23.95% | Goldman Sachs | Paul Choi | $16 → $14 | Maintains | Neutral | Get Alert |
09/22/2021 | HCM | Buy Now | HUTCHMED (China) | $18.41 | 149.86% | Goldman Sachs | Paul Choi | — | Downgrade | Buy → Neutral | Get Alert |
08/03/2021 | HCM | Buy Now | HUTCHMED (China) | $18.41 | 182.46% | Jefferies | Kelly Shi | — | Initiates | → Buy | Get Alert |
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Deutsche Bank on November 24, 2023. The analyst firm set a price target for $22.10 expecting HCM to rise to within 12 months (a possible 20.04% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Deutsche Bank, and HUTCHMED (China) upgraded their buy rating.
The last upgrade for HUTCHMED (China) Ltd happened on November 24, 2023 when Deutsche Bank raised their price target to $22.1. Deutsche Bank previously had a hold for HUTCHMED (China) Ltd.
The last downgrade for HUTCHMED (China) Ltd happened on September 22, 2021 when Goldman Sachs changed their price target from N/A to $46 for HUTCHMED (China) Ltd.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on November 24, 2023 so you should expect the next rating to be made available sometime around November 24, 2024.
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a upgraded with a price target of $20.00 to $22.10. The current price HUTCHMED (China) (HCM) is trading at is $18.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.